Fabrizio Scotti1, Paolo Milani1, Marco Setaccioli1, Silvia Maestroni2, Nicolai Sidenius3, Valentina De Lorenzi3, Amedeo Massacesi1, Fulvio Bergamini1, Gianpaolo Zerbini4. 1. Ophthalmology Department, IRCCS Istituto Auxologico Italiano, Milan, Italy. 2. Complications of Diabetes Unit, Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy. 3. Unit of Cell Matrix Signalling, IFOM The FIRC Institute of Molecular Oncology, Milan, Italy. 4. Complications of Diabetes Unit, Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy. zerbini.gianpaolo@hsr.it.
Abstract
PURPOSE: To evaluate the plasma concentration of the soluble form of the urokinase-type plasminogen activator receptor ((s)uPAR), an established biomarker of chronic inflammation, in patients affected by neovascular age-related macular degeneration. METHODS: Forty consecutive patients affected by age-related macular degeneration and 52 subjects with no history of the disease were included in this case-control study. The two groups of individuals considered for the study were matched for age, sex, and class of medications taken. Plasma concentration of suPAR was measured using a specific ELISA assay (suPARnostic, Birkeroed, Denmark). RESULTS: The case and control groups were similar for age, gender distribution, weight, height, and systolic and diastolic blood pressure, as well as for dyslipidemia and high blood pressure medication (P > 0.28). The plasma concentrations of suPAR were significantly increased in patients with neovascular age-related macular degeneration when compared to controls (6.19 ± 2.2 ng/ml, vs 5.21 ± 1.5, respectively, mean ± SD P = 0.01). CONCLUSIONS: Patients with neovascular age-related macular degeneration display increased plasma levels of suPAR, suggesting that chronic inflammation may be involved in the pathogenesis of the disease.
PURPOSE: To evaluate the plasma concentration of the soluble form of the urokinase-type plasminogen activator receptor ((s)uPAR), an established biomarker of chronic inflammation, in patients affected by neovascular age-related macular degeneration. METHODS: Forty consecutive patients affected by age-related macular degeneration and 52 subjects with no history of the disease were included in this case-control study. The two groups of individuals considered for the study were matched for age, sex, and class of medications taken. Plasma concentration of suPAR was measured using a specific ELISA assay (suPARnostic, Birkeroed, Denmark). RESULTS: The case and control groups were similar for age, gender distribution, weight, height, and systolic and diastolic blood pressure, as well as for dyslipidemia and high blood pressure medication (P > 0.28). The plasma concentrations of suPAR were significantly increased in patients with neovascular age-related macular degeneration when compared to controls (6.19 ± 2.2 ng/ml, vs 5.21 ± 1.5, respectively, mean ± SD P = 0.01). CONCLUSIONS:Patients with neovascular age-related macular degeneration display increased plasma levels of suPAR, suggesting that chronic inflammation may be involved in the pathogenesis of the disease.
Authors: Imran A Bhutto; Takayuki Baba; Carol Merges; Vikash Juriasinghani; D Scott McLeod; Gerard A Lutty Journal: Br J Ophthalmol Date: 2011-06-01 Impact factor: 4.638
Authors: R W Stephens; A N Pedersen; H J Nielsen; M J Hamers; G Høyer-Hansen; E Rønne; E Dybkjaer; K Danø; N Brünner Journal: Clin Chem Date: 1997-10 Impact factor: 8.327
Authors: Gergely Toldi; Gabriella Bekő; Gabriella Kádár; Emília Mácsai; László Kovács; Barna Vásárhelyi; Attila Balog Journal: Clin Chem Lab Med Date: 2013-02 Impact factor: 3.694
Authors: Gethin W Hodges; Casper N Bang; Kristian Wachtell; Jesper Eugen-Olsen; Jørgen L Jeppesen Journal: Can J Cardiol Date: 2015-03-25 Impact factor: 5.223
Authors: Ema Ozaki; Matthew Campbell; Anna-Sophia Kiang; Marian Humphries; Sarah L Doyle; Peter Humphries Journal: Adv Exp Med Biol Date: 2014 Impact factor: 2.622
Authors: Baoying Liu; Lai Wei; Catherine Meyerle; Jingsheng Tuo; H Nida Sen; Zhiyu Li; Sagarika Chakrabarty; Elvira Agron; Chi-Chao Chan; Michael L Klein; Emily Chew; Frederick Ferris; Robert B Nussenblatt Journal: J Transl Med Date: 2011-07-15 Impact factor: 5.531